🇺🇸 FDA
Pipeline program

LCAR-B38M CAR-T cell injection

LCAR-B38M

Phase 2 mab active

Quick answer

LCAR-B38M CAR-T cell injection for Refractory or Relapsed Multiple Myeloma is a Phase 2 program (mab) at Legend Biotech Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
Legend Biotech Corp
Indication
Refractory or Relapsed Multiple Myeloma
Phase
Phase 2
Modality
mab
Status
active

Clinical trials